Smart ligand: Aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy

Journal of Controlled Release

Volumn 171, Issue 2, 2013, Pages 152-162

  Li, Xin ^a   Zhao, Qinghe ^a   Qiu, Liyan ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Aptamer; Cancer therapy; Drug delivery; Gene delivery; Nanoparticle

Indexed keywords

DISEASES; DRUG DELIVERY; DRUG THERAPY; GENE THERAPY; GENE TRANSFER; LIGANDS; MEDICAL APPLICATIONS; NANOPARTICLES; OLIGONUCLEOTIDES; ONCOLOGY;

APTAMERS; CANCER THERAPY; CHEMOTHERAPEUTIC DRUGS; DELIVERY SYSTEMS; GENE DELIVERY; RECENT PROGRESS; TARGETED DELIVERY; TUMOR TREATMENT;

TARGETED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; APTAMER; CISPLATIN; DENDRIMER; DOXORUBICIN; GOLD NANOPARTICLE; LIPOSOME; MACROGOL; NANOPARTICLE; PHOTOSENSITIZING AGENT; POLYAMIDOAMINE; SERUM ALBUMIN; SINGLE WALLED NANOTUBE; SMALL INTERFERING RNA; STREPTAVIDIN; SUPERPARAMAGNETIC IRON OXIDE;

ATOMIC ABSORPTION SPECTROMETRY; CANCER CHEMOTHERAPY; CANCER THERAPY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENDOCYTOSIS; HYDROGEN BOND; PHOTOTOXICITY; POLYMERIZATION; PRIORITY JOURNAL; REVIEW;

APTAMER; CANCER THERAPY; DRUG DELIVERY; GENE DELIVERY; NANOPARTICLE;

ANIMALS; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NEOPLASMS; RNA, SMALL INTERFERING;

EID: 84881146974     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.06.006     Document Type: Review

References (96)

1. C. Tuerk, L. Gold, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science 249 (1990) 505-510.
2. A.D. Ellington, J.W. Szostak, In vitro selection of RNA molecules that bind specific ligands, Nature 346 (1990) 818-822.
3. Z.W. Tang, D.H. SG, K.M. Wang, H. Shi, K. Sefah, P. Mallikratchy, H.W. Chen, Y. Li, W.H. Tan, Selection of Aptamers for Molecular Recognition and Characterization of Cancer Cells, Anal. Chem. 79 (2007) 4900-4907. (Pubitemid 47051443)
4. H.S. Cho, E.C. Yeh, R. Sinha, T.A. Laurence, J.P. Bearinger, L.P. Lee, Single-step nanoplasmonic VEGF165 aptasensor for early cancer diagnosis, ACS Nano 6 (2012) 7607-7614.
5. Y.R. Wu, K. Sefah, H.P. Liu, R.W. Wang, W.H. Tan, DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells, PNAS 107 (2010) 5-10.
6. J.H. Lee, M.V. Yigit, D. Mazumdar, Y. Lu, Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates, Adv. Drug Deliv. Rev. 62 (2010) 592-605.
7. L. Cerchia, V. de Franciscis, Targeting cancer cells with nucleic acid aptamers, Trends Biotechnol. 128 (2010) 517-525.
8. C.R. Ireson, L.R. Kelland, Discovery and development of anticancer aptamers, Mol. Cancer Ther. 5 (2006) 2957-2962. (Pubitemid 46092036)
9. Z.L. Cheng, A.A. Zaki, J.Z. Hui, V.R. Muzykantov, A. Tsourkas, Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities, Science 338 (2012) 903-910.
10. M. Weaver, D.W. Laske, Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM 107) for therapy of malignant gliomas, J. Neurooncol 65 (2003) 3-13. (Pubitemid 37441310)
11. D.W. Laske, R.J. Youle, E.H. Oldfield, Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors, Nat. Med. 3 (1997) 1362-1368. (Pubitemid 28011036)
12. H. Borghaei, R.J. Schilder, Efficacy and safety of radio immunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin), Semin. Oncol. Med. 20 (2004) 4-9. (Pubitemid 38177115)
13. S. Theurich, J. Malcher, K. Wennhold, A. Shimabukuro-Vornhagen, J. Chemnitz, U. Holtick, A. Krause, C. Kobe, D. Kahraman, A. Engert, C. Scheid, G. Chakupurakal, M. Hallek, M. Bergwelt-Baildon, Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission, Am. Soc. Clin. Oncol. 31 (2013) 59-63.
14. F. Danhier, O. Feron, V. Preat, To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, J. Control. Release 148 (2010) 135-146.
15. E.L. Jin, B. Zhang, X.R. Sun, Z.X. Zhou, X.P. Ma, Q.H. Sun, J.B. Tang, Y.Q. Shen, E.V. Kirk, W.J. Murdoch, M. Radosz, Acid active cell-penetrating peptides for in vivo tumor-targeted drug delivery, J. Am. Chem. Soc. 135 (2013) 933-940.
16. W. Guo, T. Lee, J. Sudimack, R.J. Lee, Receptor-specific delivery of liposomes via folate-PEG-chol, J. Liposome Res. 10 (2000) 179-195.
17. X.B. Zhao, H. Li, R.J. Lee, Targeted drug delivery via folate receptors, Expert Opin. Drug Deliv. 5 (2008) 309-319. (Pubitemid 351454380)
18. Y.J. Lu, P.S. Low, Folate-mediated delivery of macromolecular anticancer therapeutic agents, Adv. Drug Deliv. Rev. 54 (2002) 675-693. (Pubitemid 35247522)
19. R.D. Jenison, S.C. Gill, A. Pardi, B. Polisky, High-resolution molecular discrimination by RNA, Science 263 (1994) 1425-1429. (Pubitemid 24137828)
20. S. Balamurugan, A. Obubuafo, S.A. Soper, D.A. Spivak, Surface immobilization methods for aptamer diagnostic applications, Anal. Bioanal. Chem. 390 (2008) 1009-1021. (Pubitemid 351207800)
21. K.M. Tewey, T.C. Rowe, L. Yang, B.D. Halligan, L.F. Liu, Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II, Science 226 (1984) 466-468. (Pubitemid 14012819)
22. V. Bagalkot, O.C. Farokhzad, R. Langer, S.Y. Jon, An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform, Chem. Int. Ed. Engl. 45 (2006) 8149-8152. (Pubitemid 44974149)
23. Y.A. Shieh, S.J. Yang, M.F. Wei, M.J. Shieh, Aptamer-based tumor-targeted drug delivery for photodynamic therapy, ACS Nano 4 (2010) 1433-1442.
24. Y.F. Huang, D. Shangguan, H. Liu, J.A. Phillips, X. Zhang, Y. Chen, W. Tan, Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells, Chembiochem 10 (2009) 862-868.
25. W.H. Tan, H. Wang, Y. Chen, X.B. Zhang, H.Z. Zhu, C.Y. Yang, R.H. Yang, C. Liu, Molecular aptamers for drug delivery, Trends Biotechnol. 29 (2011) 634-640.
26. S. Rana, A. Bajaj, R. Mout, V.M. Rotello, Monolayer coated gold nanoparticles for delivery applications, Adv. Drug Deliv. Rev. 64 (2012) 200-216.
27. Y.L. Luo, Y.S. Shiao, Y.F. Huang, Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy, ACS Nano 5 (2011) 7796-7804.
28. X.J. Yang, X. Liu, Z. Liu, F. Pu, J.S. Ren, X.G. Qu, Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles, Adv. Mater. 24 (2012) 2890-2895.
29. S.K. Libutti, G.F. Paciotti, A.A. Byrnes, H.R. Alexander Jr., W.E. Gannon, M. Walker, Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine, Clin. Cancer Res. 16 (2010) 6139-6149.
30. P. Bourrinet, H.H. Bengele, B. Bonnemain, A. Dencausse, J.M. Idee, P.M. Jacobs, J.M. Lewis, Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent, Invest. Radiol. 41 (2006) 313-324. (Pubitemid 44406193)
31. Y.X. Wang, S.M. Hussain, G.P. Krestin, Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging, Eur. Radiol. 11 (2001) 2319-2331. (Pubitemid 33041104)
32. R. Weissleder, G. Elizondo, J. Wittenberg, C.A. Rabito, H.H. Bengele, L. Josephson, Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging, Radiology 175 (1990) 489-493. (Pubitemid 20135290)
33. Z.A. Wang, V. Bagalkot, C.C. Vasilliou, F. Gu, F. Alexis, L.F. Zhang, M. Shaikh, K. Yuet, M.J. Cima, R. Langer, P.W. Kantoff, N.H. Bander, S.Y. Jon, O.C. Farokhzad, Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy, ChemMedChem 3 (2008) 1311-1315.
34. L.J. Meng, X.K. Zhang, Q.H. Lu, Z.F. Fei, J.P. Dyson, Single walled carbon nanotubes as drug delivery vehicles: targeting doxorubicin to tumors, Biomaterials 33 (2012) 1689-1698.
35. Z. Zhu, Z.W. Tang, J.A. Phillips, R.H. Yang, H. Wang, W.H. Tan, Regulation of singlet oxygen generation using single-walled carbon nanotubes, J. Am. Chem. Soc. 130 (2008) 10856-10857.
36. M. Bottini, S. Bruckner, K. Nika, Multi-walled carbon nanotubes induce T lymphocyte apoptosis, Toxicol. Lett. 160 (2006) 121-126. (Pubitemid 41578955)
37. C.M. Sayes, F. Liang, J.L. Hudsona, Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro, Toxicol. Lett. 161 (2006) 135-142. (Pubitemid 41790286)
38. P. Wick, P. Manser, L.K. Imbach, U.D. Weglikowska, F. Krumeich, S. Roth, W.J. Stark, A. Bruinink, The degree and kind of agglomeration affect carbon nanotube cytotoxicity, Toxicol. Lett. 168 (2007) 121-131. (Pubitemid 46054362)
39. S.V. Prylutska, I.I. Grynyuk, O.P. Matyshevska, V.M. Yashchuk, Yu.I. Prylutskyy, U. Ritter, P. Scharff, Estimation of multi-walled carbon nanotubes toxicity in vitro, Physica E 40 (2008) 2565-2569. (Pubitemid 351697750)
40. A. Wagner, M. Platzgummer, G. Kreismayr, H. Quendler, G. Stiegler, B. Ferko, G. Vecera, K. Vorauer-Uh, H. Katinger, GMP production of liposomes - A new industrial approach, J. Liposome Res. 16 (2006) 311-319. (Pubitemid 44362501)
41. H.Z. Kang, M.B. O'Donoghue, H.P. Liu, W.H. Tan, A liposome-based nanostructure for aptamer directed delivery, Chem. Commun. 46 (2010) 249-251.
42. R. Langer, Drug delivery and targeting, Nature 392 (1998) 5-10. (Pubitemid 28215187)
43. F. Alexis, E. Pridgen, L.K. Molnar, O.C. Farokhzad, Factors affecting the clearance and biodistribution of polymeric nanoparticles, Mol. Pharmacol. 5 (2008) 505-515.
44. R. Gref, Y. Minamitake, M.T. Peracchia, V. Trubetskoy, V. Torchilin, R. Langer, Biodegradable long-circulating polymeric nanospheres, Science 263 (1994) 1600-1603. (Pubitemid 24128361)
45. O.C. Farokhzad, J. Cheng, B.A. Teply, I. Sherifi, S. Jon, P.W. Kantoff, J.P. Richie, R. Langer, Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 6315-6320.
46. S. Dhar, F.X. Gu, R. Langer, O.C. Farokhzad, S.J. Lippard, Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PlGA-PEG nanoparticles, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 17356-17361.
47. S. Dhara, N. Kolishettib, S.J. Lipparda, O.C. Farokhzad, Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo, PNAS 5 (2011) 1850-1855.
48. F. Gu, L.F. Zhang, B.A. Teply, N. Mann, A. Wang, A.F. Radovic-Moreno, R. Langer, O.C. Farokhzad, Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers, PNAS 105 (2008) 2586-2591. (Pubitemid 351520557)
49. D. Dendukuri, T.A. Hatton, P.S. Doyle, Synthesis and self-assembly of amphiphilic polymeric microparticles, Langmuir 23 (2007) 4669-4674. (Pubitemid 46643206)
50. T.S. Kale, A. Klaikherd, B. Popere, S. Thayumanavan, Supramolecular assemblies of amphiphilic homopolymers, Langmuir 25 (2009) 9660-9670.
51. Y.R. Wu, K. Sefah, H.P. Liu, R.W. Wang, W.H. Tana, DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells, PNAS 107 (2010) 5-10.
52. A.B. MacAdam, Z.B. Shafi, S.L. James, C. Marriott, G.P. Martin, Preparation Of hydrophobic and hydrophilic albumin microspheres and determination of surface carboxylic acid and amino residues, Int. J. Pharm. 151 (1997) 47-55. (Pubitemid 27212303)
53. G. Wang, H. Uludag, Recent developments in nanoparticle-based drug delivery and targeting systems with emphasis on protein-based nanoparticles, Expert Opin. Drug Deliv. 5 (2008) 499-515. (Pubitemid 351877431)
54. W.J. Gradishar, Albumin-bound paclitaxel: a next-generation taxane, Expert Opin. Pharmacother. 7 (2006) 1041-1053. (Pubitemid 43949942)
55. L.L. Xie, W.J. Tong, D.H. Yu, J.Q. Xu, J. Li, C.Y. Gao, Bovine serum albumin nanoparticles modified with multilayers and aptamers for pH-responsive and targeted anti-cancer drug delivery, J. Mater. Chem. 22 (2012) 6053-6060.
56. F. Danhier, O. Feron, V. Préat, To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, J. Control. Release 148 (2010) 135-146.
57. R.K. Tekade, T. Dutta, V. Gajbhiye, N.K. Jain, Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics, J. Microencapsul. 26 (2009) 87-96.
58. M.A. Quadir, R. Haag, Biofunctional nanosystems based on dendritic polymers, J. Control. Release 161 (2012) 484-495.
59. Y. Cheng, L. Zhao, Y. Li, T. Xu, Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives, Chem. Soc. Rev. 40 (2011) 2673-2703.
60. J. Khandare, M. Calderon, N.M. Dagia, R. Haag, Multifunctional dendritic polymers in nanomedicine: opportunities and challenges, Chem. Soc. Rev. 41 (2012) 2824-2848.
61. L.M. Kaminskas, C.J.H. Porter, Targeting the lymphatics using dendritic polymers (dendrimers), Adv. Drug Deliv. Rev. 63 (2011) 890-900.
62. I.H. Lee, S. An, M.K. Yu, H.K. Kwon, S.H. Im, S.Y. Jon, Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates, J. Control. Release 3 (2011) 435-441.
63. P. Singh, U. Gupta, A. Asthana, N.K. Jain, Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice, Bioconjug. Chem. 19 (2008) 2239-2252.
64. A. Ring, I.E. Smith, M. Dowsett, Circulating tumour cells in breast cancer, Lancet Oncol. 5 (2004) 79-88. (Pubitemid 38145890)
65. A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, C.C. Mello, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature 391 (1998) 806-811. (Pubitemid 28099681)
66. G.J. Hannon, J.J. Rossi, Unlocking the potential of the human genome with RNA interference, Nature 431 (2004) 371-378. (Pubitemid 39265678)
67. L. Chaiet, F.J. Wolf, The properties of streptavidin a biotin-binding protein produced by streptomycetes, Arch. Biochem. Biophys. 106 (1964) 1-5.
68. E.O. Stapley, J.M. Mata, I.M. Miller, T.C. Demny, H.B. Woodruff, Antibiotic MSD-235. I. Production by Streptomyces avidinii and Streptomyces lavendulae, Antimicrob. Agents Chemother. (Bethesda) 161 (1963) 20-27.
69. T.C. Chu, K.Y. Twu, A.D. Ellington, M. Levy, Aptamer mediated siRNA delivery, Nucleic Acids Res. 34 (2006) 73-78.
70. A. Khaled, S. Guo, F. Li, P. Guo, Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology, Nano Lett. 5 (2005) 1797-1808. (Pubitemid 41396168)
71. S. Guo, N. Tschammer, S. Mohammed, P. Guo, Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA, Hum. Gene Ther. 16 (2005) 1097-1110.
72. J.O. McNamara II, E.R. Andrechek, Y. Wang, K.D. Viles, R.E. Rempe, E. Gilboa, B.A. Sullenger, P.H. Giangrande, Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras, Nat. Biotechnol. 24 (2006) 1005-1015. (Pubitemid 44215395)
73. J.P. Dassie, X.Y. Liu, G.S. Thomas, R.M. Whitaker, K.W. Thiel, K.R. Stockdale, D.K. Meyerholz, A.P. McCaffrey, J.O. McNamara II, P.H. Giangrande, Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors, Nat. Biotechnol. 27 (2009) 839-846.
74. U. Wullner, I. Neef, A. Eller, M. Kleines, M.K. Tur, S. Barth, Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2, Curr. Cancer Drug Targets 8 (2008) 554-565.
75. C.L. Beisel, T.S. Bayer, K.G. Hoff, C.D. Smolke, Model-guided design of ligand-regulated RNAi for programmable control of gene expression, Mol. Syst. Biol. 4 (2008) 224.
76. Q.Q. Zhao, J.L. Chen, T.F. Lv, C.X. He, G.P. Tang, W.Q. Liang, Y. Tabata, J.Q. Gao, N/P ratio significantly influences the transfection efficiency and cytotoxicity of a polyethylenimine/chitosan/DNA complex, Biol. Pharm. Bull. 32 (2009) 706-710.
77. J.S. Park, K. Na, D.G. Woo, H.N. Yang, J.M. Kim, J.H. Kim, H.M. Chung, K.H. Park, Non-viral gene delivery of DNA polyplexed with nanoparticles transfected into human mesenchymal stem cells, Biomaterials 31 (2010) 124-132.
78. S.Y. Lee, M.S. Huh,S. Lee, S.J. Lee, H. Chung, J.H. Park, Y.K. Oh,K. Choi,K. Kim, I.C. Kwon, Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing, J. Control. Release 141 (2010) 339-346.
79. N.X. Zhao, H.G. Bagaria, M.S. Wong, Y.L. Zu, A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma, J. Nanobiotechnol. 9 (2011) 2.
80. V. Bagalkot, X.H. Gao, siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing, ACS Nano 5 (2011) 8131-8139.
81. J.H. Zhou, H.T. Li, S. Li, J. Zaia, J.J. Rossi, Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy, Mol. Ther. 16 (2008) 1481-1489.
82. M. Dominska, D.M. Dykxhoorn, Breaking down the barriers: siRNA delivery and endosome escape, J. Cell Sci. 123 (2010) 1183-1189.
83. Y.K. Oh, T.G. Park, siRNA delivery systems for cancer treatment, Adv. Drug Deliv. Rev. 61 (2009) 850-862.
84. E. Frei, Combination cancer therapy: presidential address, Cancer Res. 32 (1972) 2593-2607.
85. J. Hongrapipat, P. Kopeckova, J. Liu, S. Prakongpan, J. Kopecek, Combination chemotherapy and photodynamic therapy with Fab? fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells, Mol. Pharm. 5 (2008) 696-709.
86. N. Wiradharma, Y.W. Tong, Y. Yang, Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect, Biomaterials 30 (2009) 3100-3109.
87. H. Lee, M. Hu, R.M. Reilly, C. Allen, Apoptotic epidermal growth factor (EGF)-conjugated block copolymer micelles as a nanotechnology platform for targeted combination therapy, Mol. Pharm. 4 (2007) 769-781. (Pubitemid 350004277)
88. L. Zhang, A.F. Radovic-Moreno, F. Alexis, F.X. Gu, P.A. Basto, V. Bagalkot, S. Jon, R.S. Langer, O.C. Farokhzad, Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates, ChemMedChem 2 (2007) 1268-1271.
89. N. Kolishetti, S. Dharc, P.M. Valenciad, L.Q. Lind, R. Karnike, S.J. Lippard, R. Langer, O.C. Farokhzad, Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy, PNAS 107 (2010) 17939-17944.
90. S. Yadav, L.E. van Vlerken, S.R. Little, M.M. Amiji, Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells, Cancer Chemother. Pharmacol. 63 (2009) 711-722.
91. H. Meng, M. Liong, T. Xia, Z. Li, Z. Ji, J.I. Zink, Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line, ACS Nano 4 (2010) 4539-4550.
92. Y. Chen, S.R. Bathula, J. Li, L. Huang, Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer, J. Biol. Chem. 285 (2010) 22639-22650.
93. Y.B. Patil, S.K. Swaminathan, T. Sadhukha, L. Ma, J. Panyam, The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance, Biomaterials 31 (2010) 358-365.
94. E.J. Kim, Y.Y. Jung, H. Choi, J. Yang, J.S. Suh, Y.M. Huh, K.H. Kim, S. Haam, Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex, Biomaterials 31 (2010) 4592-4599.
95. L.C. Griffin, G.F. Tidmarsh, L.C. Bock, J.J. Toole, L.L. Leung, In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits, Blood 81 (1993) 3271-3276. (Pubitemid 23172909)
96. D.S. Seferos, A.E. Prigodich, D.A. Giljohann, P.C. Patel, C.A. Mirkin, Polyvalent DNA nanoparticle conjugates stabilize nucleic acids, Nano Lett. 9 (2009) 308-311.